ARTES Biotechnology has announced a collaboration with global pharmaceutical company, Boehringer Ingelheim Animal Health. ARTES Biotechnology specialises in recombinant protein production, process and vaccine development from microbial expression systems. ARTES’ expression system Hansenula polymorpha is the preferred technology for affordable mass vaccination and recommended by the World Health Organization (WHO) for these purposes. In combination with ARTES’ METAVAX® platform, this offers a new, unique and economical approach to low-cost mass production of safe and effective vaccines required in the veterinary field.
US – Governor Terry E. Branstad travelled to Sioux Center last week to attend the grand opening for one of three Boehringer Ingelheim Vetmedica, Inc. (BIVI) specialised vaccine research facilities.
BARCELONA, SPAIN - An important anniversary in the history of porcine circovirus type 2 (PCV2) has been marked at a special international pig veterinary satellite symposium held in Barcelona, Spain in June 2011 as part of the 6th International Symposium on Emerging and Re-emerging Pig Diseases.
4th Boehringer Ingelheim Expert Forum on Farm-Animal Well-Being
US - Boehringer Ingelheim Vetmedica, Inc has launched two initiatives on Porcine Epidemic Diarrhoea (PED) for swine industry; it has announced applied research funding and a PED News service for vets.
US - In the latest 'At the Meeting' (ATM) audio program on swine health from the Morrison Group, leading swine veterinarians take on the historic and novel work regarding porcine circovirus (PCV2), including prevention, new diagnostic methods and vertical transmission’s impact on pig production and sow herds.
Boehringer Ingelheim’s market leading Animal Health medication Metacam® (active ingredient: Meloxicam) obtained EU wide marketing authorisation as an oral suspension in a concentration of 15 mg/ml for use in pigs.
Get the latest news on Swine Health Subscribe to our newsletter